Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 multicenter randomized semi-single blind study to compare efficacy and safety of high-dose short duration daptomycin with conventional therapy in complicated skin and skin structure infections due to Gram-positive bacteria

Next Previous
Trial Profile

Phase 2 multicenter randomized semi-single blind study to compare efficacy and safety of high-dose short duration daptomycin with conventional therapy in complicated skin and skin structure infections due to Gram-positive bacteria

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daptomycin (Primary) ; Penicillins; Vancomycin; Vancomycin
  • Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Sponsors Cubist Pharmaceuticals

    • Most Recent Events

    • 01 Sep 2008 Results published in International Journal of Clinical Practice.
    • 17 Oct 2007 Status changed from recruiting to completed.
    • 20 Feb 2007 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top